In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Savara (SVRA – Research Report), with a price ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
The Food and Drug Administration (FDA) has approved Journavxâ„¢ (suzetrigine) for the treatment of moderate to severe acute pain in adults.
LANGHORNE, Pa. - Savara Inc. (NASDAQ:SVRA), a biopharmaceutical company specializing in rare respiratory diseases with a ...
NYU’s Student Government Assembly will allow all students to vote in its chair elections, a process reserved for SGA ...
Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings ...
Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...
On 30 January 2025, the World Health Organization (WHO) announced that Niger has been verified for eliminating the transmission of onchocerciasis, commonly known as river blindness. The Mectizan ...
Tiger Group is offering more than 700 lots of pro-grade audiovisual gear from full-service rental house C Mount, a leader in the custom production solutions space and a trusted resource for the film ...
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...
Just over five years since his arrest and arraignment on charges that he masterminded the murder of Daphne Caruana Galizia, ...
Here is a list of matters listed at Sunshine Magistrates' Court on Tuesday. Today's court listings are published as part of News Corporation's commitment to public interest journalism and are compiled ...